Reporting results from a first-in-human phase Iclinical trial, researchers have found that treatment with cirmtuzumab measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells.
Contributed Author:
Scott LaFee, University of California San Diego
Topics:
More From BioPortfolio on "Phase 1 Trial Finds Experimental Drug Safe in Treating Chronic Lymphocytic Leukemia"